Cytokinetics, Incorporated (CYTK) — Analyst outlook / Analyst consensus target is. Based on 34 analyst ratings, the consensus is bullish — 32 Buy, 2 Hold.
The consensus price target is $92.27 (low: $69.00, high: $136.00), representing an upside of 39.1% from the current price $66.35.
Analysts estimate Earnings Per Share (EPS) of $-5.19 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.26 vs est $-5.19 (missed -1.4%). 2025: actual $-6.54 vs est $-6.49 (missed -0.8%). Analyst accuracy: 99%.
CYTK Stock — 12-Month Price Forecast
$92.27
▲ +39.07% Upside
Average Price Target
Based on 34 Wall Street analysts offering 12-month price targets for Cytokinetics, Incorporated, the average price target is $92.27, with a high forecast of $136.00, and a low forecast of $69.00.
The average price target represents a +39.07% change from the last price of $66.35.
Highest Price Target
$136.00
Average Price Target
$92.27
Lowest Price Target
$69.00
CYTK Analyst Ratings
Buy
Based on 34 analysts giving stock ratings to Cytokinetics, Incorporated in the past 3 months
EPS Estimates — CYTK
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.26
vs Est –$5.19
▼ 1.4% off
2025
Actual –$6.54
vs Est –$6.49
▼ 0.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CYTK
52%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.018B
vs Est $0.003B
▲ 82.7% off
2025
Actual $0.088B
vs Est $0.077B
▲ 12.7% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
